Keyword: United Therapeutics
United Therapeutics faces allegations of illegally blocking Remodulin generics by teaming with a devicemaker.
Sandoz launched a generic to United Therapeutics' Remodulin, which pulled in about $500 million in the U.S. last year.
An industrywide probe of pharma's charitable contributions has spawned multimillion-dollar settlements, and Actelion is the latest to deal with the feds.
J&J's retiring Group Worldwide Chair Sandra Peterson, with $17.18 million in 2017 compensation, was the top-paid female biopharma exec.
Amid an industrywide probe, Lundbeck reached a tentative settlement wrapping up its own copay charity allegations.
For a smaller pharma company like United Therapeutics, losing patent protection on a big drug is especially painful. Remodulin, approved in 2002, loses exclusivity this summer, meaning the company will soon face off against cheap competition to its biggest top-line contributor.
More than a year after starting to probe pharma's ties with patient assistance charities, the feds have secured their first sizable settlement.
Astellas has joined the biopharma who's who of companies to disclose federal scrutiny for donations to charities that help patients cover drug costs.
The patient assistance charity named in a plea agreement against Aegerion has acknowledged the DOJ wants more info on its methods.
United Therapeutics was built on Remodulin. The company grew out of a career change for CEO Martine Rothblatt, who built Sirius satellite radio before getting into pharma. Her son’s diagnosis of pulmonary arterial hypertension inspired the move—and Remodulin, which was approved in 2002.